Atara Biotherapeutics ATRA Stock
Atara Biotherapeutics Price Chart
Atara Biotherapeutics ATRA Financial and Trading Overview
| Atara Biotherapeutics stock price | 7.32 USD |
| Previous Close | 2.09 USD |
| Open | 2.09 USD |
| Bid | 0 USD x 2900 |
| Ask | 0 USD x 3200 |
| Day's Range | 1.96 - 2.19 USD |
| 52 Week Range | 1.45 - 9.34 USD |
| Volume | 2.35M USD |
| Avg. Volume | 1.71M USD |
| Market Cap | 209.66M USD |
| Beta (5Y Monthly) | 0.94507 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -11.41 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.27 USD |
ATRA Valuation Measures
| Enterprise Value | 71.78M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.1263158 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.6472213 |
| Price/Book (mrq) | 3.1797922 |
| Enterprise Value/Revenue | 1.249 |
| Enterprise Value/EBITDA | -0.28 |
Trading Information
Atara Biotherapeutics Stock Price History
| Beta (5Y Monthly) | 0.94507 |
| 52-Week Change | -63.54% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.34 USD |
| 52 Week Low | 1.45 USD |
| 50-Day Moving Average | 2.34 USD |
| 200-Day Moving Average | 3.6 USD |
ATRA Share Statistics
| Avg. Volume (3 month) | 1.71M USD |
| Avg. Daily Volume (10-Days) | 2.41M USD |
| Shares Outstanding | 97.97M |
| Float | 75.79M |
| Short Ratio | 6.64 |
| % Held by Insiders | 1.62% |
| % Held by Institutions | 103.98% |
| Shares Short | 12.62M |
| Short % of Float | 13.22% |
| Short % of Shares Outstanding | 12.87% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -454.55% |
| Gross Margin | 121.90% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -46.70% |
| Return on Equity (ttm) | -148.62% |
Income Statement
| Revenue (ttm) | 57.49M USD |
| Revenue Per Share (ttm) | 0.56 USD |
| Quarterly Revenue Growth (yoy) | -83.20% |
| Gross Profit (ttm) | 63.57M USD |
| EBITDA | -256026000 USD |
| Net Income Avi to Common (ttm) | -214968000 USD |
| Diluted EPS (ttm) | -2.34 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 205.41M USD |
| Total Cash Per Share (mrq) | 2.1 USD |
| Total Debt (mrq) | 67.53M USD |
| Total Debt/Equity (mrq) | 103.95 USD |
| Current Ratio (mrq) | 3.303 |
| Book Value Per Share (mrq) | 0.673 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -224330000 USD |
| Levered Free Cash Flow (ttm) | -162083248 USD |
Profile of Atara Biotherapeutics
| Country | United States |
| State | CA |
| City | Thousand Oaks |
| Address | 2380 Conejo Spectrum Street |
| ZIP | 91320 |
| Phone | 805 623 4211 |
| Website | https://www.atarabio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 330 |
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Q&A For Atara Biotherapeutics Stock
What is a current ATRA stock price?
Atara Biotherapeutics ATRA stock price today per share is 7.32 USD.
How to purchase Atara Biotherapeutics stock?
You can buy ATRA shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Atara Biotherapeutics?
The stock symbol or ticker of Atara Biotherapeutics is ATRA.
Which industry does the Atara Biotherapeutics company belong to?
The Atara Biotherapeutics industry is Biotechnology.
How many shares does Atara Biotherapeutics have in circulation?
The max supply of Atara Biotherapeutics shares is 6.08M.
What is Atara Biotherapeutics Price to Earnings Ratio (PE Ratio)?
Atara Biotherapeutics PE Ratio is now.
What was Atara Biotherapeutics earnings per share over the trailing 12 months (TTM)?
Atara Biotherapeutics EPS is -11.41 USD over the trailing 12 months.
Which sector does the Atara Biotherapeutics company belong to?
The Atara Biotherapeutics sector is Healthcare.
Atara Biotherapeutics ATRA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Biotechnology Total Retu XNBI | 4470.08 USD — |
-1.41
|
— — | 4446.23 USD — | 4506.67 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8504.39 USD — |
+1.34
|
— — | 8367.19 USD — | 8515.13 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 21278.67 USD — |
+1.26
|
— — | 20945.45 USD — | 21305.05 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}